Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NP99

UPID:
TREM1_HUMAN

ALTERNATIVE NAMES:
Triggering receptor expressed on monocytes 1

ALTERNATIVE UPACC:
Q9NP99; B4DWG2; K7EJW1; Q53FL8; Q5T2C9; Q86YU1

BACKGROUND:
The Triggering receptor expressed on myeloid cells 1, also known as TREM1, acts as a cell surface receptor amplifying inflammatory signals from bacterial and fungal infections. By engaging with transmembrane adapter TYROBP/DAP12, TREM1 initiates a cascade promoting the release and migration of pro-inflammatory agents, amplifying innate immune responses. Additionally, TREM1 serves as a decoy receptor, modulating its own pro-inflammatory activity.

THERAPEUTIC SIGNIFICANCE:
Exploring the intricate functions of TREM1 offers a promising avenue for developing novel therapeutic interventions aimed at modulating immune responses in diseases characterized by excessive inflammation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.